|
|
|
|
|
非在研适应症- |
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期- |
针对阿片类依赖者应用丁丙诺啡(美沙酮)脱毒或诱导桥接引入盐酸噻吩诺啡片进行防复吸治疗,及既定用药方案下,患者对盐酸噻吩诺啡片耐受的观察,为IIa期试验针对该目标受试者人群的给药方案设计提供依据。
盐酸噻吩诺啡片预防阿片类依赖者脱毒后复吸有效性与安全性的多中心、双盲、随机对照II期临床研究
通过评价盐酸噻吩诺啡片在阿片类依赖者脱毒后预防复吸的有效性与安全性,为后续试验给药方案确定提供科学依据.
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase Ⅱb Clinical Trial of Thienorphine Hydrochloride Tablets for the Efficacy, Safety, and Optimal Dosing of Relapse Prevention After Opioid Dependence Detoxification
Opioid addiction is common worldwide. Thienorphine hydrochloride is a newly partial opioid receptor agonist drugs. It's affinity with opioid receptors was much higher than opioids, which could effectively prevents opioid dependence by stop opioids competition for opioid receptors and causing opioid dependence. The aim of this research was to determine whether thienorphine hydrochloride would reduce opioid use and better preventing relapse among opioid addicts.
100 项与 北京紫都宏业科技发展有限公司 相关的临床结果
0 项与 北京紫都宏业科技发展有限公司 相关的专利(医药)
100 项与 北京紫都宏业科技发展有限公司 相关的药物交易
100 项与 北京紫都宏业科技发展有限公司 相关的转化医学